MAR 31, 2020 9:00 AM PDT

Impact of liquid biopsy in advanced HER2+ breast cancer tumors: a follow-up study

Speaker
  • Post-Doctoral Fellow
    Biography
      Dr. Allegretti has devoted his entire training and career to cancer research, initially focusing on hematological malignancies before transitioning to solid tumors. He began his career at the Sapienza University of Rome working on human NK cells. After obtaining a Bachelor's degree in Biotechnology, he moved on to another lab within the same University where he worked on different translational studies with targeted agents, which reinforced his interest in oncology. Since getting a PhD degree in 2015, he added experiences in managing primary samples, cells and different types of molecular and cellular biology techniques through his internship. Two years later at the end of 2017, he moved to IRCCS Regina Elena National Cancer Institute where he led studies on monoclonal antibodies against the HER2 receptor by developing innovative liquid biopsy workflows from scratch. Dr. Allegretti was particularly interested in monitoring tumor evolution in different cancer settings through clinical follow-up of patients with colorectal, breast, sarcoma, lung, and thyroid carcinomas. Dr. Allegretti has been responsible for all liquid biopsy analysis of cancer patients discussed within his Molecular Tumor Board since 2019. In parallel, he manages several liquid biopsy research projects focused on breast cancer, which he considers an innovative and exciting research area.

    Abstract
    DATE:  March 31, 2020
    TIME:  9:00am PT, 12:00pm ET
     
    HER2-positive breast cancer is a type of breast cancer caused by over-expression of a protein called human epidermal growth factor receptor 2 (HER2). While this aggressive breast cancer is highly curable, with 10 year survival rates at an average of >70%, it is also highly prevalent – with this gene mutation being detected in 1 out of every 5 breast cancer cases. In addition to chemotherapy, there are multiple targeted therapies approved for treatment of HER2+ breast cancer. However, HER2+ breast cancer also has a high recurrence rate, increasing the chances of the cancer metastasizing.
     
    In today's presentation, Dr. Allegretti will discuss his clinical research work on HER2+ metastatic breast cancer samples using liquid biopsy (LB) analysis. This study aims to determine feasibility of profiling and tracking over time the molecular behavior of advanced HER2+ breast cancer tumors during drug treatments. Analysis is conducted using two different LB techniques - next-generation sequencing (NGS) and digital PCR (dPCR). Results strongly encourage the integration of LB analysis with genomic assessment from tumor tissues. Together, these complementary techniques may be able to provide compelling evidence to uncover resistance/response mechanisms in the future, potentially yielding valuable clinical information for better cancer management strategies.
     
    Learning Objectives:
    • Investigate advantages of analyzing advanced HER2+ metastatic breast cancer tumor samples with Liquid Biopsy 
    • Demonstrate the complementary nature of dPCR and NGS Liquid Biopsy analysis
    • Illustrate the advantages of combined tissue biopsy and Liquid Biopsy analyses
     
     
     
    Webinars will be available for unlimited on-demand viewing after live event.
     
    LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

     


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    OCT 08, 2020 7:00 AM PDT
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    DEC 02, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    AUG 25, 2020 8:00 AM PDT
    C.E. CREDITS
    AUG 25, 2020 8:00 AM PDT
    DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    Loading Comments...
    Show Resources
    Attendees
    • See more